Sipuleucel-T (PROVENGE)

The first FDA-approved cellular immunotherapy used to treat cancer was approved for use in patients with advanced prostate cancer which is asymptomatic or minimally symptomatic. Patient’s immune cells are stimulated to attack and kill cancer cells. Immune cells are isolated from a patient’s blood, stimulated in a laboratory and are returned to the clinic where they are infused into the patient.